ArticleJournal of advanced research2026
Dual rescue mission: P-G3 dendrimer addresses ovarian and neuroendocrine roots of obesity-linked subfertility.
Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe dual pathology of obesity-induced infertility, which encompasses both peripheral (ovarian) and central (hypothalamic-pituitary) mechanisms, is well documented. However, existing therapeutic approaches do not target these two pathways concurrently within the context of obesity-related reproductive dysfunction.
objectivesThis study aims to evaluate the effectiveness of P-G3, a novel therapeutic agent that targets both local (ovarian) and systemic (hypothalamic-pituitary axis) levels, in treating obesity-related subfertility in female mice.
methodsWe adopted a diet-induced obese (DIO) female mouse model to investigate the effect of P-G3. Its effectiveness was evaluated through assessments of metabolic parameters, adipose tissue morphology, estrous cyclicity, and fertility outcomes. To elucidate mechanisms, we analysed pituitary LH secretion and employed advanced neurogenetic tools. Specifically, we applied cFos-TetO lineage tracing coupled with RNA sequencing to profile activated hypothalamic neurons and in vivo multichannel electrophysiology to firstly monitor GnRH neuronal electrical activity within this context.
resultsP-G3 significantly reduced overall obesity (by 7.32 g in 8 weeks), especially in the abdominal and peri-ovarian regions, and improved metabolic issues. At the ovary, P-G3 reduced inflammation and enhanced follicular development. At the pituitary, P-G3 enhanced the responsiveness to kisspeptin-54, increasing LH pulse frequency and mean LH level by over 60 % at the proestrus stage. At the hypothalamus, transcriptomics revealed major changes in pathways for energy metabolism and GnRH signalling. Additionally, P-G3 significantly enhanced GnRH neuronal firing, with the pulse-like discharge frequency and amplitude increasing by 91 % and 70 %, respectively. Finally, P-G3 alleviated estrous cycle disorders, increasing cycle regularity by 70 % and reducing mating to birth latency by 4.5 days.
conclusionP-G3 nanomedicine provides a pioneering dual-scale therapeutic strategy for treating obesity-induced infertility by concurrently alleviating local ovarian adipocyte pathologies and inflammatory and restoring systemic central reproductive axis function, i.e., hypothalamic GnRH activity and pituitary responsiveness, thus comprehensively rescuing folliculogenesis and fertility.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.